TransCode Therapeutics (RNAZ) Competitors $9.11 +0.42 (+4.83%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$8.70 -0.41 (-4.50%) As of 07/14/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. ENLV, COEP, TPST, NRSN, CVKD, CGTX, ALXO, CARA, TENX, and OVIDShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Tenax Therapeutics Ovid Therapeutics TransCode Therapeutics (NASDAQ:RNAZ) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Which has higher valuation & earnings, RNAZ or ENLV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$16.75MN/AN/AEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.94 Do institutionals & insiders have more ownership in RNAZ or ENLV? 1.0% of Enlivex Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to RNAZ or ENLV? In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 beat Enlivex Therapeutics' score of 1.87 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TransCode Therapeutics Very Positive Enlivex Therapeutics Very Positive Is RNAZ or ENLV more profitable? Enlivex Therapeutics' return on equity of -57.67% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -578.88% -222.61% Enlivex Therapeutics N/A -57.67%-50.52% Do analysts recommend RNAZ or ENLV? TransCode Therapeutics presently has a consensus target price of $280.00, indicating a potential upside of 2,973.55%. Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 681.25%. Given TransCode Therapeutics' higher probable upside, equities research analysts plainly believe TransCode Therapeutics is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk & volatility, RNAZ or ENLV? TransCode Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. SummaryEnlivex Therapeutics beats TransCode Therapeutics on 8 of the 11 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.59M$2.42B$5.54B$9.14BDividend YieldN/A1.70%5.01%4.00%P/E RatioN/A9.1928.6919.45Price / SalesN/A461.68373.1779.78Price / CashN/A22.3424.7227.47Price / Book-0.174.708.255.58Net Income-$16.75M$30.99M$3.19B$252.81M7 Day Performance-1.51%3.04%3.53%2.11%1 Month Performance30.70%22.83%9.56%11.87%1 Year Performance-99.97%-3.74%30.54%16.61% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.7506 of 5 stars$9.11+4.8%$280.00+2,973.5%-100.0%$7.59MN/A0.009Positive NewsENLVEnlivex Therapeutics2.868 of 5 stars$1.21+2.5%$10.00+726.4%-13.5%$27.91MN/A-1.8370COEPCoeptis Therapeutics0.5239 of 5 stars$7.73+2.5%N/A+65.6%$26.49M$62.87K-1.332TPSTTempest Therapeutics2.37 of 5 stars$7.08-0.7%$30.00+323.7%-76.2%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.4853 of 5 stars$2.09+9.4%$14.00+569.9%+98.0%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.7896 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404Positive NewsCGTXCognition Therapeutics2.9536 of 5 stars$0.58+42.9%$2.83+389.5%-69.4%$25.11MN/A-0.7820Analyst DowngradeGap UpHigh Trading VolumeALXOALX Oncology3.5826 of 5 stars$0.44-3.5%$3.30+643.2%-93.4%$24.57MN/A-0.1840News CoverageCARACara Therapeutics0.2263 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.6792 of 5 stars$5.75-1.0%$17.50+204.3%+76.5%$24.10MN/A-2.329Positive NewsOVIDOvid Therapeutics4.7197 of 5 stars$0.37+10.5%$3.13+735.6%-58.4%$24.06M$570K-1.0760High Trading Volume Related Companies and Tools Related Companies Enlivex Therapeutics Competitors Coeptis Therapeutics Competitors Tempest Therapeutics Competitors NeuroSense Therapeutics Competitors Cadrenal Therapeutics Competitors Cognition Therapeutics Competitors ALX Oncology Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Ovid Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts